Hari P, et al. - Researchers investigated the efficacy of atorvastatin vs placebo for the treatment of hyperlipidemia in children with steroid-resistant nephrotic syndrome (SRNS), given that dyslipidemia is a cardiovascular risk factor in SRNS. In this prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial, they administered a fixed dose of atorvastatin (n = 15, 10 mg/d) or placebo (n = 15) by block randomization in a 1:1 ratio to 30 patients with SRNS, aged 5–18 years, with serum low-density lipoprotein cholesterol levels between 130 and 300 mg/dl. No benefits on lowering lipid levels were seen with atorvastatin treatment, when given at a fixed daily dose of 10 mg in children with SRNS; no significant effect was seen in other lipid fractions, carotid intima-media thickness and flow-mediated dilation of the brachial artery. Increased serum albumin was found to be related to improvement in dyslipidemia.